CLINICAL TRIALS PROFILE FOR NEBIVOLOL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Nebivolol Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00125853 ↗ | The Effect of Nebivolol on Insulin Sensitivity | Completed | Foundation for Circulatory Health | N/A | 2006-07-01 | The purpose of this study is to conduct a randomised trial to compare the insulin sensitivity, 24 hour blood pressure profile, and tolerability of nebivolol plus a thiazide-like diuretic versus atenolol plus a thiazide-like diuretic. |
| NCT00125853 ↗ | The Effect of Nebivolol on Insulin Sensitivity | Completed | Imperial College London | N/A | 2006-07-01 | The purpose of this study is to conduct a randomised trial to compare the insulin sensitivity, 24 hour blood pressure profile, and tolerability of nebivolol plus a thiazide-like diuretic versus atenolol plus a thiazide-like diuretic. |
| NCT00142584 ↗ | Evaluation of the Long-Term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension | Completed | Mylan Bertek Pharmaceuticals | Phase 3 | 2005-08-01 | The purpose of this study is to evaluate long-term safety,tolerability and blood pressure effects of metoprolol versus nebivolol in patients with hypertension. These drugs may be given alone or in combination with other drugs that are commonly used in the treatment of hypertension |
| NCT00145210 ↗ | Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans | Completed | Mylan Bertek Pharmaceuticals | Phase 3 | 2005-04-01 | The purpose of this study is to evaluate the effects of nebivolol on blood pressure and heart rate in African American patients with hypertension. |
| NCT00145236 ↗ | Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension | Completed | Mylan Bertek Pharmaceuticals | Phase 3 | 2001-11-01 | The purpose of this study was to determine if nebivolol is superior to placebo for the treatment of elevated blood pressure in Black patients with mild to moderate hypertension. |
| NCT00158093 ↗ | A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo | Completed | Mylan Bertek Pharmaceuticals | Phase 1 | 2003-06-01 | Nebivolol is one of a class of drugs known as beta-blockers. These drugs are useful in the treatment of high blood pressure, angina, abnormal heart rhythms and following a heart attack. The purpose of this study is to explore the potential of nebivolol to cause a certain type of abnormal heart rhythm, known as QTc prolongation. The potential of nebivolol to cause this adverse event will be compared to three other drugs: atenolol, a beta-blocker approved by the FDA; Avelox (moxifloxacin), an anti-biotic approved for use by the FDA which is known to cause QTc prolongation; and placebo, a drug look-alike that contains no drug. The working hypothesis was that 20 or 40 mg of nebivolol would not prolong corrected QT intervals measured during peak nebivolol concentrations (i.e., 2 hours after dosing) on Day 7. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Nebivolol Hydrochloride
Condition Name
Clinical Trial Locations for Nebivolol Hydrochloride
Trials by Country
Clinical Trial Progress for Nebivolol Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Nebivolol Hydrochloride
Sponsor Name
